黑色素瘤免疫介导的不良事件综述
A Review of Immune-Mediated Adverse Events in Melanoma.
作者信息
Kennedy Lucy Boyce, Salama April K S
机构信息
Hematology/Oncology, Duke University, Durham, NC, USA.
Division of Medical Oncology, Duke University, Durham, NC, USA.
出版信息
Oncol Ther. 2019 Dec;7(2):101-120. doi: 10.1007/s40487-019-0096-8. Epub 2019 Jul 8.
Abstract
The use of checkpoint inhibitor-based immunotherapy has transformed the treatment landscape for melanoma as well as many other cancer types. With the ability to potentiate tumor-specific immune responses, these agents can result in durable tumor control. However, this activation of the immune system can lead to a unique constellation of side effects, distinct from other cancer therapies, collectively termed immune-mediated adverse events (irAEs). This review will focus on irAEs and guidelines for management related to the most clinically relevant checkpoint inhibitors, those that target programmed death receptor-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4).
摘要
基于检查点抑制剂的免疫疗法的应用已经改变了黑色素瘤以及许多其他癌症类型的治疗格局。这些药物能够增强肿瘤特异性免疫反应，从而实现持久的肿瘤控制。然而，免疫系统的这种激活会导致一系列独特的副作用，与其他癌症疗法不同，这些副作用统称为免疫介导的不良事件（irAEs）。本综述将聚焦于irAEs以及与临床上最相关的检查点抑制剂（即靶向程序性死亡受体-1（PD-1）和细胞毒性T淋巴细胞相关抗原4（CTLA-4）的抑制剂）相关的管理指南。
相似文献
1
A Review of Immune-Mediated Adverse Events in Melanoma.黑色素瘤免疫介导的不良事件综述
Oncol Ther. 2019 Dec;7(2):101-120. doi: 10.1007/s40487-019-0096-8. Epub 2019 Jul 8.
2
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.抗程序性死亡-1药物治疗后不良事件的管理
Oncologist. 2016 Oct;21(10):1230-1240. doi: 10.1634/theoncologist.2016-0055. Epub 2016 Jul 8.
3
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
4
Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.免疫检查点抑制剂在临床实践中的应用：免疫相关毒性管理的最新进展。
Transl Lung Cancer Res. 2015 Oct;4(5):560-75. doi: 10.3978/j.issn.2218-6751.2015.06.06.
5
Toxicity management of immunotherapy for patients with metastatic melanoma.免疫治疗转移性黑色素瘤患者的毒性管理。
Ann Transl Med. 2016 Jul;4(14):272. doi: 10.21037/atm.2016.07.10.
6
Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines.免疫检查点抑制剂治疗相关免疫相关不良事件的管理：当前临床指南的小型综述
Asia Pac J Oncol Nurs. 2019 Apr-Jun;6(2):154-160. doi: 10.4103/apjon.apjon_3_19.
7
Immunological Agents Used in Cancer Treatment.用于癌症治疗的免疫制剂。
Eurasian J Med. 2019 Feb;51(1):90-94. doi: 10.5152/eurasianjmed.2018.18194. Epub 2018 Nov 30.
8
Safety of pembrolizumab for the treatment of melanoma.帕博利珠单抗治疗黑色素瘤的安全性。
Expert Opin Drug Saf. 2015 Jun;14(6):957-64. doi: 10.1517/14740338.2015.1021774. Epub 2015 Apr 30.
9
What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events.关于癌症免疫疗法我们了解多少？长期生存和免疫相关不良事件。
Allergol Immunopathol (Madr). 2019 May-Jun;47(3):303-308. doi: 10.1016/j.aller.2018.04.005. Epub 2018 Jul 6.
10
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.纳武单抗联合伊匹单抗或单独使用纳武单抗治疗晚期黑色素瘤相关的神经系统严重不良事件，包括一组脑炎病例
Oncologist. 2017 Jun;22(6):709-718. doi: 10.1634/theoncologist.2016-0487. Epub 2017 May 11.
引用本文的文献
1
Self-delivering RNAi immunotherapeutic PH-762 silences PD-1 to generate local and abscopal antitumor efficacy.自我递送的RNAi免疫疗法PH-762使PD-1沉默以产生局部和远隔抗肿瘤疗效。
Front Immunol. 2024 Dec 4;15:1501679. doi: 10.3389/fimmu.2024.1501679. eCollection 2024.
2
Melanoma crash course.黑色素瘤速成课程。
Can Fam Physician. 2024 Apr;70(4):254-257. doi: 10.46747/cfp.7004254.
3
Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.辅助 PD-1 抑制剂治疗 III/IV 期黑色素瘤切除术后患者的免疫相关甲状腺不良事件的频率和特征：一项全国性队列研究。
Support Care Cancer. 2024 Apr 10;32(5):281. doi: 10.1007/s00520-024-08445-y.
4
Commentary: 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration.评论：基于人群分析的皮肤黑色素瘤31基因表达谱检测与生存结果：一项监测、流行病学和最终结果（SEER）合作研究
J Clin Aesthet Dermatol. 2023 Dec;16(12 Suppl 1):S9-S11.
5
Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.11β-羟类固醇脱氢酶 1 对糖皮质激素的激活作用限制了黑色素瘤中 T 细胞驱动的干扰素信号转导和对 PD-1 阻断的反应。
J Immunother Cancer. 2023 Apr 7;11(4):e004150. doi: 10.1136/jitc-2021-004150.
6
Case series: Immune checkpoint inhibitor-induced transverse myelitis.病例系列：免疫检查点抑制剂诱发的横贯性脊髓炎。
Front Neurol. 2023 Feb 21;14:1130313. doi: 10.3389/fneur.2023.1130313. eCollection 2023.
7
The Roles of MiRNAs (MicroRNAs) in Melanoma Immunotherapy.miRNAs（微小 RNA）在黑色素瘤免疫治疗中的作用。
Int J Mol Sci. 2022 Nov 25;23(23):14775. doi: 10.3390/ijms232314775.
8
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine.PD-1 靶向免疫疗法改变了季节性流感疫苗的滤泡辅助性 T 细胞和体液免疫应答。
Nat Immunol. 2022 Aug;23(8):1183-1192. doi: 10.1038/s41590-022-01274-3. Epub 2022 Jul 28.
9
Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma.将病毒溶瘤与其他免疫疗法联合用于治疗黑色素瘤的前景。
Front Mol Biosci. 2022 Apr 14;9:777775. doi: 10.3389/fmolb.2022.777775. eCollection 2022.
10
Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.免疫治疗或靶向治疗转移性黑色素瘤患者的皮肤副作用和皮肤不良反应类型：一项回顾性单中心研究。
Dermatol Ther. 2022 Jun;35(6):e15492. doi: 10.1111/dth.15492. Epub 2022 May 10.
本文引用的文献
1
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study.帕博利珠单抗治疗HIV合并晚期癌症患者安全性评估——一项1期研究
JAMA Oncol. 2019 Sep 1;5(9):1332-1339. doi: 10.1001/jamaoncol.2019.2244.
2
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.临床试验中 PD-1 和 PD-L1 抑制剂的治疗相关不良反应：系统评价和荟萃分析。
JAMA Oncol. 2019 Jul 1;5(7):1008-1019. doi: 10.1001/jamaoncol.2019.0393.
3
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.评估纳武利尤单抗联合伊匹木单抗用于晚期黑色素瘤患者的两种剂量方案：来自 IIIb/IV 期 CheckMate 511 试验的结果。
J Clin Oncol. 2019 Apr 10;37(11):867-875. doi: 10.1200/JCO.18.01998. Epub 2019 Feb 27.
4
Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review.免疫检查点抑制剂治疗在 HIV 感染和晚期癌症患者中的安全性和疗效：系统评价。
JAMA Oncol. 2019 Jul 1;5(7):1049-1054. doi: 10.1001/jamaoncol.2018.6737.
5
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy.循环细胞因子可预测接受抗 PD-1 免疫治疗的黑色素瘤患者的免疫相关毒性。
Clin Cancer Res. 2019 Mar 1;25(5):1557-1563. doi: 10.1158/1078-0432.CCR-18-2795. Epub 2018 Nov 8.
6
Immune Checkpoint Inhibitor Toxicity.免疫检查点抑制剂毒性。
Curr Oncol Rep. 2018 Jul 31;20(9):72. doi: 10.1007/s11912-018-0718-6.
7
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease.免疫检查点抑制剂在患有癌症和已有自身免疫性疾病患者治疗中的应用。
Ann Intern Med. 2018 Jul 17;169(2):133-134. doi: 10.7326/L18-0209.
8
New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity.NCCN 指南更新：免疫治疗相关毒性的识别与管理。
J Natl Compr Canc Netw. 2018 May;16(5S):594-596. doi: 10.6004/jnccn.2018.0047.
9
Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced Enteritis.维多珠单抗在治疗难治性免疫检查点抑制剂诱导的肠炎中的新作用。
ACG Case Rep J. 2018 Feb 28;5:e17. doi: 10.14309/crj.2018.17. eCollection 2018.
10
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.
Zotero 插件